The 'Cocaine Blues' and Other Problems in Epidemiologic Studies of Vitamin D and Cancer

Nutrition Reviews

Volumn 65, Issue SUPPL.2, 2007, Pages

  Schwartz, Gary G ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; VITAMIN; VITAMIN D;

EVIDENCE BASED MEDICINE; HUMAN; NEOPLASM; REVIEW; RISK FACTOR;

ANTICARCINOGENIC AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASMS; RISK FACTORS; VITAMIN D; VITAMINS;

EID: 35148881588     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2007.tb00344.x     Document Type: Article

References (15)

1. Schwartz GG, Skinner HG. Vitamin D and cancer: new insights. Curr Opin Clin Nutr Metab Care 2007;10:S6-S11.
2. Schwartz GG., Vitamin D. and the natural history of prostate cancer: from theory to therapy. Ann Epidemiol 2007, in press.
3. Hansen CM, Binderup L., Hamberg KJ, Carlberg C. Vitamin D and cancer: effects of 1, 25(OH)2D3 and its analogs on growth control and tumorigenesis. Front Biosci 2001;6:SD820-SD848.
4. Heaney RP. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr 2004;80:S1706s-S1709s.
5. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing new effective dietary intake recommendations for vitamin D. J Nutr 2005;135:S317-S322.
6. Nesby-O'Dell S., Scanlon KS, Cogswell ME, Gillespie C., Hollis BW, Looker AC, et al. Hypovita-minosis D prevalence and determinants among African American and white women of reproductive age: Third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr 2002;76:S187-S192.
7. Chesney RW, Rosen JF, Hanstra AJ, Smith C., Ma-haffey K., DeLuca HF. Absence of seasonal variation in serum concentrations of 1, 25-dihydroxyvitamin D despite a rise in 25-hydroxyvitamin D in summer. J Clin Endocrin Metab 1981;53:S139-S143.
8. Schwartz GG, Whitlatch LW, Chen C., Lokeshwar BL, Holick MF. Human prostate cells synthesize 1, 25 dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomark Prev 1998;7:S391-S395.
9. Schwartz GG, Eads D., Rao A., Cramer SD, Willing-ham MC, Chen TC, et al. Pancreatic cancer cells express 25-hydroxyvitamin D-1-a-hydroxylase and their proliferation is inhibited by the prohormone, 25-hydroxyvitamin D3. Carcinogenesis 2004;25:S1015-S1020.
10. Konety BR, Schwartz GG, Acierno JS, Becich MJ, Getzenberg RH. The role of vitamin D in normal prostatic growth and development. Cell Growth Differentiation 1996;7:S1563-S1570.
11. John E., Koo J., Schwartz GG. Sun exposure and prostate cancer risk: evidence for a protective effect of early life exposure. Cancer Epidemiol. Biomark Prev, 2007;16:S1283-S1286.
12. Schwartz GG. Vitamin D and the epidemiology of prostate cancer. Seminars in Dialysis 2005;18:S276-S289.
13. Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, Lokeshwar BL, et al. 25-Hy-droxyvitamin D-1-alpha-hydroxylase is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol 2002;81:S135-S140.
14. Schwartz GG, Hall MC, Stindt D., Patton S., Lovato J., Torti TM. A phase I/II trial of 19-nor-1-a -dihydroxyvitamin D2 (Paricalcitol) in advanced andro-gen-insentive prostate cancer. Clin Cancer Res 2005;11:S8680-S8685.
15. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GX, Ruetter JD, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel in an-drogen-independent prostate cancer: a report from the ASCENT investigators. J Clin Oncol 2007;25:S669-S674.